The curcumin analog HO-3867 selectively kills cancer cells by converting mutant p53 protein to transcriptionally active wildtype p53.

doi:10.1074/jbc.RA117.000950

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The curcumin analog HO-3867 selectively kills cancer cells by converting mutant p53 protein to transcriptionally active wildtype p53.

The Journal of biological chemistry - 23 Mar 2018

Madan Esha, Parker Taylor M, Bauer Matthias R, Dhiman Alisha, Pelham Christopher J, Nagane Masaki, Kuppusamy M Lakshmi, Holmes Matti, Holmes Thomas R, Shaik Kranti, Shee Kevin, Kiparoidze Salome, Smith Sean D, Park Yu-Soon A, Gomm Jennifer J, Jones Louise J, Tomás Ana R, Cunha Ana C, Selvendiran Karuppaiyah, Hansen Laura A, Fersht Alan R, Hideg Kálmán, Gogna Rajan, Kuppusamy Periannan

Abstract excerpt

p53 is an important tumor-suppressor protein that is mutated in more than 50% of cancers. Strategies for restoring normal p53 function are complicated by the oncogenic properties of mutant p53 and have not met with clinical success. To counteract mutant p53 activity, a variety of drugs with the potential to reconvert mutant p53 to an active wildtype form have been developed. However, these drugs are associated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Apoptosis

Share to Curcumin

Share to Mice, Nude

Share to Mutant Proteins

Share to Tumor Cells, Cultured

Share to Tumor Suppressor Protein p53

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 29382728
DOI: 10.1074/jbc.RA117.000950
PMCID: PMC5868245

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The curcumin analog HO-3867 selectively kills cancer cells by converting mutant p53 protein to transcriptionally active wildtype p53.PMID 29382728Read ↗

Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer.Semantic proximity Read ↗

Targeting Mutant-p53 for Cancer Treatment: Are We There Yet?Semantic proximity Read ↗

Targeting Oncogenic Mutant p53 for Cancer TherapySemantic proximity Read ↗

Side-Stepping the Guardian of the Genome: Current Cancer Therapeutics Targeting Mutant p53Semantic proximity Read ↗

Natural Modulators of the TP53 Pathway: Potential Herbal and Plant-Derived Agents for Cancer Therapy.Semantic proximity Read ↗

Drugging p53 in cancer: one protein, many targets.Semantic proximity Read ↗

Targeting p53 for Novel Anticancer TherapySemantic proximity Read ↗

Mutant p53 rescue and modulation of p53 redox state.Semantic proximity Read ↗

Mutant p53-Associated Molecular Mechanisms of ROS Regulation in Cancer CellsSemantic proximity Read ↗

The p53 Pathway as a Target in Cancer Therapeutics: Obstacles and PromiseSemantic proximity Read ↗

Pharmacological activation of p53 in cancer cells.Semantic proximity Read ↗

Administration of 4‑hexylresorcinol increases p53‑mediated transcriptional activity in oral cancer cells with the p53 mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.